GabapentinCat. No. 0806 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 1-(Aminomethyl)cyclohexaneacetic acid |
Biological Activity
Anticonvulsant with several possible mechanisms of action. Increases GABA in the brain and binds to a novel site associated with voltage-sensitive Ca2+ channels. Prevents neuronal death and is antinociceptive and anxiolytic.Licensing Information
Sold for research purposes under agreement from Pfizer Inc.Certificate of Analysis / Safety Data Sheet
References
Upton (1994) Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings. TiPS 15 456. PMID: 7886818.
Taylor et al (1998) A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 29 233. PMID: 9551785.
Fink et al (2000) Inhibition of Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br.J.Pharmacol. 130 900. PMID: 10864898.
Timmerman et al (2000) A microdialysis study on the mechanism of action of gabapentin. Eur.J.Pharmacol. 398 53. PMID: 10856447.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Gabapentin, supplier, Anticonvulsant, Increases, brain, GABA, Binds, voltage-sensitive, Ca2+, channels, GABAB, Receptors, GABAA, GABAC, Calcium, CaV, Channels, L-Type, P-Type, R-Type, Q-Type, T-Type, N-Type, voltage-gated, voltage-dependent, Pfizer
Quick Order
Find multiple products by catalog number
New Products in this Area
Potent and selective S1P4 agonist
H2L5186303Potent and selective LPA2 receptor antagonist
MEDICA 16FFA1 (GPR40) agonist. Also inhibits ATP citrate lyase
BX 471Potent, selective CCR1 antagonist
PF 04418948Potent and selective EP2 receptor antagonist
LatanoprostFP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptors
GRI 977143Selective LPA2 receptor non-lipid agonist
CYM 50260Potent and selective S1P4 agonist
G-36Selective GPR30 antagonist
Strontium chlorideCalcium sensing receptor (CaSR) agonist
CS 2100Selective S1P1 agonist
SMANT hydrochlorideInhibits Smoothened (Smo) accumulation
TUG 891Potent and selective GPR120 agonist
IT1t dihydrochloridePotent CXCR4 antagonist
RuBi GABA trimethylphosphineCaged GABA; inhibits neural activity
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.






